In the 2027 Medicare Advantage (MA) and Part D rate announcement, CMS highlighted risk adjustment accuracy, payment integrity, and accountability for diagnoses that drive reimbursement.
CMS recently launched the Medicare GLP-1 Bridge, a short-term demonstration that provides eligible Part D beneficiaries with access to certain glucagon‐like peptide‐1 (GLP-1) drugs for $50 per month.
CMS released the fiscal year (FY) 2027 Inpatient Prospective Payment System (IPPS) final rule last week, outlining upcoming changes to Medicare payment rates and policies for inpatient services.
